Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the ongoing telmisartan alone and in combination with ramipril global end point trial and the telmisartan randomized assessment study in ACE intolerant subjects with cardiovascular disease

Paolo Verdecchia, Peter Sleight, Giuseppe Mancia, Robert Fagard, Bruno Trimarco, Roland E. Schmieder, Jae Hyung Kim, Garry Jennings, Petr Jansky, Jyh Hong Chen, Lisheng Liu, Peggy Gao, Jeffrey Probstfield, Koon Teo, Salim Yusuf

Research output: Contribution to journalArticle

83 Citations (Scopus)

Abstract

BACKGROUND-: Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers reduce left ventricular hypertrophy (LVH). The effect of these drugs on LVH in high-risk patients without heart failure is unknown. METHODS AND RESULTS-: In the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET), patients at high vascular risk and tolerant of ACE inhibitors were randomly assigned to ramipril, telmisartan, or their combination (n=23 165). In the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease (TRANSCEND), patients intolerant of ACE inhibitors were randomized to telmisartan or placebo (n=5343). Prevalence of LVH at entry in TRANSCEND was 12.7%. It was reduced by telmisartan (10.5% and 9.9% after 2 and 5 years) compared with placebo (12.7% and 12.8% after 2 and 5 years) (overall odds ratio, 0.79; 95% confidence interval [CI], 0.68 to 0.91; P=0.0017). New-onset LVH occurred less frequently with telmisartan compared with placebo (overall odds ratio, 0.63; 95% CI, 0.51 to 0.79; P=0.0001). LVH regression was similar in the 2 groups. In ONTARGET, prevalence of LVH at entry was 12.4%. At follow-up, it occurred slightly less frequently with telmisartan (odds ratio, 0.92; 95% CI, 0.83 to 1.01; P=0.07) and the combination (odds ratio, 0.93; 95% CI, 0.84 to 1.02; P=0.12) than with ramipril, but differences between the groups were not significant. New-onset LVH was associated with a higher risk of primary outcome during follow-up (hazard ratio, 1.77; 95% CI, 1.50 to 2.07). CONCLUSIONS-: In patients at high vascular risk, telmisartan is more effective than placebo in reducing LVH. New-onset LVH is reduced by 37%. The effect of combination of the 2 drugs on LVH is similar to that of ramipril alone.

Original languageEnglish
Pages (from-to)1380-1389
Number of pages10
JournalCirculation
Volume120
Issue number14
DOIs
Publication statusPublished - Oct 2009

Fingerprint

Ramipril
Left Ventricular Hypertrophy
Peptidyl-Dipeptidase A
Blood Vessels
Cardiovascular Diseases
Confidence Intervals
Odds Ratio
Placebos
Angiotensin-Converting Enzyme Inhibitors
telmisartan
Angiotensin Receptor Antagonists
Drug Combinations
Heart Failure

Keywords

  • Angiotensin
  • Electrocardiography
  • Epidemiology
  • Hypertrophy
  • Prognosis

ASJC Scopus subject areas

  • Physiology (medical)
  • Cardiology and Cardiovascular Medicine

Cite this

Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the ongoing telmisartan alone and in combination with ramipril global end point trial and the telmisartan randomized assessment study in ACE intolerant subjects with cardiovascular disease. / Verdecchia, Paolo; Sleight, Peter; Mancia, Giuseppe; Fagard, Robert; Trimarco, Bruno; Schmieder, Roland E.; Kim, Jae Hyung; Jennings, Garry; Jansky, Petr; Chen, Jyh Hong; Liu, Lisheng; Gao, Peggy; Probstfield, Jeffrey; Teo, Koon; Yusuf, Salim.

In: Circulation, Vol. 120, No. 14, 10.2009, p. 1380-1389.

Research output: Contribution to journalArticle

Verdecchia, Paolo ; Sleight, Peter ; Mancia, Giuseppe ; Fagard, Robert ; Trimarco, Bruno ; Schmieder, Roland E. ; Kim, Jae Hyung ; Jennings, Garry ; Jansky, Petr ; Chen, Jyh Hong ; Liu, Lisheng ; Gao, Peggy ; Probstfield, Jeffrey ; Teo, Koon ; Yusuf, Salim. / Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the ongoing telmisartan alone and in combination with ramipril global end point trial and the telmisartan randomized assessment study in ACE intolerant subjects with cardiovascular disease. In: Circulation. 2009 ; Vol. 120, No. 14. pp. 1380-1389.
@article{02793afbd10d44c2a6428f1ac0a6355e,
title = "Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the ongoing telmisartan alone and in combination with ramipril global end point trial and the telmisartan randomized assessment study in ACE intolerant subjects with cardiovascular disease",
abstract = "BACKGROUND-: Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers reduce left ventricular hypertrophy (LVH). The effect of these drugs on LVH in high-risk patients without heart failure is unknown. METHODS AND RESULTS-: In the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET), patients at high vascular risk and tolerant of ACE inhibitors were randomly assigned to ramipril, telmisartan, or their combination (n=23 165). In the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease (TRANSCEND), patients intolerant of ACE inhibitors were randomized to telmisartan or placebo (n=5343). Prevalence of LVH at entry in TRANSCEND was 12.7{\%}. It was reduced by telmisartan (10.5{\%} and 9.9{\%} after 2 and 5 years) compared with placebo (12.7{\%} and 12.8{\%} after 2 and 5 years) (overall odds ratio, 0.79; 95{\%} confidence interval [CI], 0.68 to 0.91; P=0.0017). New-onset LVH occurred less frequently with telmisartan compared with placebo (overall odds ratio, 0.63; 95{\%} CI, 0.51 to 0.79; P=0.0001). LVH regression was similar in the 2 groups. In ONTARGET, prevalence of LVH at entry was 12.4{\%}. At follow-up, it occurred slightly less frequently with telmisartan (odds ratio, 0.92; 95{\%} CI, 0.83 to 1.01; P=0.07) and the combination (odds ratio, 0.93; 95{\%} CI, 0.84 to 1.02; P=0.12) than with ramipril, but differences between the groups were not significant. New-onset LVH was associated with a higher risk of primary outcome during follow-up (hazard ratio, 1.77; 95{\%} CI, 1.50 to 2.07). CONCLUSIONS-: In patients at high vascular risk, telmisartan is more effective than placebo in reducing LVH. New-onset LVH is reduced by 37{\%}. The effect of combination of the 2 drugs on LVH is similar to that of ramipril alone.",
keywords = "Angiotensin, Electrocardiography, Epidemiology, Hypertrophy, Prognosis",
author = "Paolo Verdecchia and Peter Sleight and Giuseppe Mancia and Robert Fagard and Bruno Trimarco and Schmieder, {Roland E.} and Kim, {Jae Hyung} and Garry Jennings and Petr Jansky and Chen, {Jyh Hong} and Lisheng Liu and Peggy Gao and Jeffrey Probstfield and Koon Teo and Salim Yusuf",
year = "2009",
month = "10",
doi = "10.1161/CIRCULATIONAHA.109.865774",
language = "English",
volume = "120",
pages = "1380--1389",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "14",

}

TY - JOUR

T1 - Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the ongoing telmisartan alone and in combination with ramipril global end point trial and the telmisartan randomized assessment study in ACE intolerant subjects with cardiovascular disease

AU - Verdecchia, Paolo

AU - Sleight, Peter

AU - Mancia, Giuseppe

AU - Fagard, Robert

AU - Trimarco, Bruno

AU - Schmieder, Roland E.

AU - Kim, Jae Hyung

AU - Jennings, Garry

AU - Jansky, Petr

AU - Chen, Jyh Hong

AU - Liu, Lisheng

AU - Gao, Peggy

AU - Probstfield, Jeffrey

AU - Teo, Koon

AU - Yusuf, Salim

PY - 2009/10

Y1 - 2009/10

N2 - BACKGROUND-: Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers reduce left ventricular hypertrophy (LVH). The effect of these drugs on LVH in high-risk patients without heart failure is unknown. METHODS AND RESULTS-: In the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET), patients at high vascular risk and tolerant of ACE inhibitors were randomly assigned to ramipril, telmisartan, or their combination (n=23 165). In the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease (TRANSCEND), patients intolerant of ACE inhibitors were randomized to telmisartan or placebo (n=5343). Prevalence of LVH at entry in TRANSCEND was 12.7%. It was reduced by telmisartan (10.5% and 9.9% after 2 and 5 years) compared with placebo (12.7% and 12.8% after 2 and 5 years) (overall odds ratio, 0.79; 95% confidence interval [CI], 0.68 to 0.91; P=0.0017). New-onset LVH occurred less frequently with telmisartan compared with placebo (overall odds ratio, 0.63; 95% CI, 0.51 to 0.79; P=0.0001). LVH regression was similar in the 2 groups. In ONTARGET, prevalence of LVH at entry was 12.4%. At follow-up, it occurred slightly less frequently with telmisartan (odds ratio, 0.92; 95% CI, 0.83 to 1.01; P=0.07) and the combination (odds ratio, 0.93; 95% CI, 0.84 to 1.02; P=0.12) than with ramipril, but differences between the groups were not significant. New-onset LVH was associated with a higher risk of primary outcome during follow-up (hazard ratio, 1.77; 95% CI, 1.50 to 2.07). CONCLUSIONS-: In patients at high vascular risk, telmisartan is more effective than placebo in reducing LVH. New-onset LVH is reduced by 37%. The effect of combination of the 2 drugs on LVH is similar to that of ramipril alone.

AB - BACKGROUND-: Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers reduce left ventricular hypertrophy (LVH). The effect of these drugs on LVH in high-risk patients without heart failure is unknown. METHODS AND RESULTS-: In the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET), patients at high vascular risk and tolerant of ACE inhibitors were randomly assigned to ramipril, telmisartan, or their combination (n=23 165). In the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease (TRANSCEND), patients intolerant of ACE inhibitors were randomized to telmisartan or placebo (n=5343). Prevalence of LVH at entry in TRANSCEND was 12.7%. It was reduced by telmisartan (10.5% and 9.9% after 2 and 5 years) compared with placebo (12.7% and 12.8% after 2 and 5 years) (overall odds ratio, 0.79; 95% confidence interval [CI], 0.68 to 0.91; P=0.0017). New-onset LVH occurred less frequently with telmisartan compared with placebo (overall odds ratio, 0.63; 95% CI, 0.51 to 0.79; P=0.0001). LVH regression was similar in the 2 groups. In ONTARGET, prevalence of LVH at entry was 12.4%. At follow-up, it occurred slightly less frequently with telmisartan (odds ratio, 0.92; 95% CI, 0.83 to 1.01; P=0.07) and the combination (odds ratio, 0.93; 95% CI, 0.84 to 1.02; P=0.12) than with ramipril, but differences between the groups were not significant. New-onset LVH was associated with a higher risk of primary outcome during follow-up (hazard ratio, 1.77; 95% CI, 1.50 to 2.07). CONCLUSIONS-: In patients at high vascular risk, telmisartan is more effective than placebo in reducing LVH. New-onset LVH is reduced by 37%. The effect of combination of the 2 drugs on LVH is similar to that of ramipril alone.

KW - Angiotensin

KW - Electrocardiography

KW - Epidemiology

KW - Hypertrophy

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=70349972814&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349972814&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.109.865774

DO - 10.1161/CIRCULATIONAHA.109.865774

M3 - Article

VL - 120

SP - 1380

EP - 1389

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 14

ER -